|
|
 |
|
|
SCIENCE NEWS
Endoscopic Findings of Cytomegalovirus Gastritis
A research team from Japan demonstrated the endoscopic findings of cytomegalovirus gastritis after allogeneic hematopoietic stem cell transplantation in addition to its clinical features. [Press release from EurekAlert! discussing online prepublication in the World Journal of Gastroenterology]
Researchers Shed Light on Common Juvenile Cancer
A team of researchers have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. [Press release from Université de Montréal discussing online prepublication in Genes and Development]
|
|
INDUSTRY NEWS
Affymax and Takeda Announce Phase III Trials Meet Primary Endpoints for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure With Some Differences Noted in Secondary Analyses
Affymax, Inc. and Takeda Global Research & Development Center, Inc., announced preliminary top-line results from the Phase III clinical program for the investigational drug, Hematide(TM)/peginesatide, for the treatment of anemia in chronic renal failure patients. [Affymax, Inc. Press Release]
CIRM Commits $25 Million to Overcome Immune Rejection of Stem Cell Therapies
The Governing Board of the California Institute for Regenerative Medicine, the state stem cell agency created by proposition 71, approved $25 million to fund 19 projects intended to overcome immune rejection of transplanted stem cells. [California Institute for Regenerative Medicine Press Release]
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg®
Pfizer Inc. announced that based on discussions with the U.S. Food and Drug Administration, it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia) in the United States and that it will be voluntarily withdrawing the new drug application. [Pfizer Inc. Press Release]
ImmunoGen, Inc. Earns Milestone with Start of SAR650984 Clinical Trial
ImmunoGen, Inc. announced that Sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. [ImmunoGen, Inc. Press Release]
Tarix Pharmaceuticals' TXA127 Receives FDA Orphan Drug Designation for Stem Cell Engraftment
Tarix Pharmaceuticals announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. [PR Newswire]
|
|
POLICY NEWS
National Heart, Lung, and Blood Institute Funds Research to Improve Safety of Red Blood Cell Transfusions
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. [The National Heart, Lung, and Blood Institute Press Release]
NICE Unable to Recommend Cancer Drug in Draft Guidance Owing to Lack of Robust Data
In preliminary draft guidance, a new treatment for patients with a form of leukemia has not been recommended for use in the National Health Service (NHS) because evidence does not yet show how well the drug works compared with current NHS treatment, for the price the NHS is being asked to pay. [The National Institute for Health and Clinical Excellence (NICE), United Kingdom]
NIBIB and the Indian Department of Biotechnology Collaborate to Develop Low-Cost Medical Devices
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) announced the availability of supplemental funding for eligible NIBIB-supported research grants to facilitate collaborative work among researchers in the United States and India. [National Institutes of Health, United States]
Center for Scientific Review; Notice of Closed Meetings [National Institutes of Health, United States]
Extension of Expiration Date and Additional Receipt Dates for RFA-AI-10-014: Ancillary Studies in Immunomodulation Clinical Trials (R01) (NOT-AI-10-035) [National Institutes of Health, United States]
Development of Articles for Rare Diseases [Food and Drug Administration, United States]
July 26-27, 2010: Meeting of the Blood Products Advisory Committee Announcement [Food and Drug Administration, United States]
|
|
EVENTS
Translational Cancer Medicine 2010 - USA
July 11-14, 2010
San Francisco, United States
United Kingdom National Stem Cell Network (UKNSCN) Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom
Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland
Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland
Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland
The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain
International Society for Cellular Therapy (ISCT) - Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy
Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States
Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia
Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States
American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States
Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany
52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Senior Scientist - Magnetic Cell Separation (STEMCELL Technologies)
Business Development Manager Europe - Cell Therapy Products (Pall Corporation)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
Visit here to post your career opportunities.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit!
Comments or Suggestions? Email info@connexoncreative.com with your feedback.
|
|
|
|
|
|
|
|
|
